A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THREE DIFFERENT DOSES OF LAS100977, ADMINISTERED BY INHALATION DURING 7 DAYS TO STABLE ASTHMA PATIENTS

Trial Profile

A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THREE DIFFERENT DOSES OF LAS100977, ADMINISTERED BY INHALATION DURING 7 DAYS TO STABLE ASTHMA PATIENTS

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2014

At a glance

  • Drugs Abediterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 03 Nov 2012 Planned patient number is 20 according to European Clinical Trials Database record.
    • 27 Mar 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top